Publications by authors named "Laura T Jones"
J Oncol Pharm Pract
December 2012
Article Synopsis
- The study aimed to compare the cost-effectiveness of two doses of the drug fulvestrant (250 mg vs. 500 mg) in postmenopausal women with advanced breast cancer after previous treatments.
- A Markov model over 24 months indicated that the 500 mg dose was more effective in improving progression-free survival, with an incremental cost-effectiveness of about US$10,972 per month.
- The findings suggest that the 500 mg dose is cost-effective as long as the willingness to pay threshold is at least US$15,000 per month, yet the 250 mg dose remains a viable alternative.
